NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

BRIEF-Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim

Published 2016-05-19, 07:08 a/m
© Reuters.  BRIEF-Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim
HZNP
-

May 19 (Reuters) - Horizon Pharma Plc HZNP.O
* Says anticipates a reduction to 2016 adjusted ebitda of
approximately $10 million versus prior guidance
* Also licensed u.s., european and canadian intellectual
property rights for interferon gamma-1b for treatment of
friedreich's ataxia
* Under terms of separate agreement with undisclosed third
party, co licensed u.s., european, canadian ip rights for
interferon gamma-1b
* Co will immediately begin investing in related
manufacturing, supply chain, regulatory,commercial activities
for interferon gamma-1b
* To immediately begin investing in related manufacturing,
supply chain, regulatory and commercial activities for
interferon gamma-1b
* Paid boehringer ingelheim eur5 million upon signing, will
pay eur20 million upon closing for rights for interferon
gamma-1b in territories outside u.s, canada, japan
* To Acquire Worldwide Rights To Interferon Gamma-1B from
boehringer ingelheim international gmbh

Source text for Eikon: ID:nMKWQVYY1a
Further company coverage: HZNP.O

(Bengaluru Newsroom: +1-646-223-8780)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.